Kornimate/medical-research-clean huggingface dataset:
laparoscopic appendectomy by multi-port vs single port.

Conditions: Acute Appendicitis

Summary: laparoscopic appendectomy (la) is nowadays considered the gold standard in fertile women affected by uncomplicated appendicitis. the level of evidence for benefits from la in this subgroup is high. since the dissemination of single access surgery (no-scars surgery) ameliorated outcome has been supposed in these patients regarding post-operative pain, hospital stay and cosmetics results, and keeping the same safety as la. this randomized controlled study is supposed to give answers to these questions.


Eligibility criteria:
inclusion criteria: * age: 14-60 * american society of anesthesiologists (asa) score: i-iii * absence of non-correctable coagulopathy (international normalized ratio \>1,5, or platelet count \<90 × 109/l). * diagnosis: acute appendicitis with surgical indication exclusion criteria: * complicated appendicitis after exploration or previously diagnosed (ct) * psychical inability * pregnancy
real-life outcomes of taf/ftc/bic in hiv patients in colombia

Conditions: HIV Treatment

Summary: hiv remains a major global health issue, with 38 million people affected, and significant challenges in diagnosis and treatment due to stigma and socioeconomic factors. in colombia, the epidemic is concentrated among men who have sex with men, with 165,405 people living with hiv and 14,670 new cases reported in 2023. barriers to treatment access are exacerbated by social factors and venezuelan migration. while integrase inhibitors like taf/ftc/bic have shown effectiveness, real-world data in colombia is limited. this study evaluates adherence, effectiveness, and clinical outcomes of taf/ftc/bic in 169 patients within the eps sura program, contributing context-specific evidence.


Eligibility criteria:
inclusion criteria: * male or female patients aged 18 years or older. * individuals with a confirmed hiv diagnosis. * individuals enrolled in eps sura during the study period. * patients receiving treatment with the taf/ftc/bic regimen. exclusion criteria: * patients with a concurrent diagnosis of tuberculosis. * pregnant patients during the study period. * patients with virologic failure. * patients who started treatment with taf/ftc/bic but changed providers or discontinued treatment before completing six months of therapy.
mechanisms of immune deficiency

Conditions: Immune Deficiency

Summary: 1. the purpose of this study is to learn more about the changes in genes, cells and proteins that cause immune deficiency diseases. 2. the early stages of the study will focus on two groups of patients: 1. members of families in which several persons have symptoms or medical histories that suggest immune deficiency. 2. patients who have received treatments with medications or drugs that affect functions of the immune system (secondary immune deficiencies). it is hoped that studies will provide guidelines for extension of the research to other patient groups. up to 200 patients and family members will be invited to participate.

the experiments that are proposed in this portion of the study are intended to: 1. characterize the significance of the variant form of ezh2 identified in this family. they will characterize the degree of methylation of lysine 27 of histone h3 in subjects with the variant and members of the same family who have the wild type gene. the functional methyltransferase activity of the variant and wild type genes will be measured. 2. characterize the current status of b-cell maturation and function in subjects with either the variant gene and the wild type gene. 3. characterize b-cell function (antibody production) and the quality of antibody produced after immunizations in subjects with the wild type gene or the variant gene.

Eligibility criteria:
inclusion criteria: 1. immunodeficiency disease; or 2. family member of individual with immunodeficiency disease exclusion criteria: 1. persons with immune deficiencies that are secondary to other diseases such as malignancies. 2. persons who do not have immune deficiencies, persons who are not meet eligibility criteria
clinical application of pcr-based diagnosis of community-onset viral respiratory infections.

Conditions: Acute Respiratory Tract Infection

Summary: viral respiratory infections are common worldwide. it has been suggested that nucleic acid amplification tests, enabling a rapid etiologic diagnosis, may be useful in reducing antibiotic prescriptions rates. the objective of this study was to evaluate if access to a multiplex real-time pcr method would have an impact on antibiotic prescriptions for acute respiratory tract infections (artis), in primary care. adult patients with respiratory tract infections will be prospectively included. nasopharyngeal and throat swabs will be analyzed with a multiplex real-time pcr method, targeting 13 viruses and two bacteria. samples will be collected during the winter season (october-april). patients will be open-label randomised to receive a rapid result (the following day) or a delayed result (after 10+/-2 days). the investigators are planning to include approximately 400 patients. prescription of antibiotics will be measured at initial visit as well as at a follow-up visit 10+/-2 days later. primary endpoint is antibiotic prescription in the acute phase (initial visit) and secondary endpoint antibiotic treatment (ongoing or initiated) at follow-up visit. the hypohesis is that access to a method with the ability of providing a rapid etiologic diagnosis of respiratory infections will affect the use of antibiotics in outpatient care of adult patients with arti.


Eligibility criteria:
inclusion criteria: * age 18 years or older * at least two of the following symptoms: coryza, congestion, sneezing, sore throat, odynophagi, cough, chest pain, shortness of breath or fever for which teh physician found no other explanation. * symptom duration of less than 14 days exclusion criteria: * \>14 days of symptoms * confirmed bacterial infection * hospital acquired infection (\>3days in hospital)
the role of plin5 in the development of nonalcoholic fatty liver disease.

Conditions: Non-alcoholic Fatty Liver Disease

Summary: to further clarify the role of sequence polymorphism in patatin-like phospholipid domain containing protein 3 in the development of nonalcoholic fatty liver disease.

a sequence polymorphism in patatin-like phospholipid domain containing protein 3 is significantly associated with nonalcoholic fatty liver disease, but its mechanism underlying this association remains obscure. we introduce the human samples of liver to clarify the relationship between the expression of plin5 and the development of sequence polymorphism in patatin-like phospholipid domain containing protein 3 variant-associated nonalcoholic fatty liver disease, analyze the lipid metabolism and lipotoxicity of hepatocytes to elucidate the mechanisms of plin5 in the development of sequence polymorphism in patatin-like phospholipid domain containing protein 3 variant-associated nonalcoholic fatty liver disease. our study will contribute to the mechanism of nonalcoholic fatty liver disease, and its prevention and therapy.

Eligibility criteria:
inclusion criteria: the diagnosis of simple fatty liver disease was confirmed by clinical presentation, ultrasound, and without long-term drinking history, viral hepatitis, medication history, obesity (bmi≥30), type 2 diabetes and other metabolic diseases. exclusion criteria: with long-term drinking history, viral hepatitis, medication history, obesity (bmi≥30), type 2 diabetes and other metabolic diseases.

Keywords: nonalcoholic fatty liver disease lipid droplets plin5
efficacy of udenafil after radical resection for sigmoid colon and rectal cancer

Conditions: Erectile Dysfunction; Sigmoid Colon Cancer; Rectal Cancer

Summary: the purpose of this study is to evaluate the efficacy of udenafil (zydena®, dong-a pharmaceutical co., ltd, seoul, korea) in treatment of erectile dysfunction after radical resection for sigmoid colon and rectal cancer. in this study, the efficacy of udenafil will be evaluated in treatment for patient with chronic erectile dysfunction, which developed after radical resection for sigmoid and rectal cancer and continues 12 months after the surgery.

post-pelvic surgery erectile dysfunction is of much interest to those performing sigmoid colon and rectal cancer surgery and their patients. erectile dysfunction has been recognized to develop from damage to pelvic parasympathetic nerve, which are especially vulnerable during anterior rectal dissection. there may be also a contribution of psychological factors from the presence of stoma and fear of recurrent cancer. recently, several studies reported that erectile dysfunction after rectal excision for rectal cancer was completely reversed or satisfactorily improved using oral erectile dysfunction drugs. udenafil is a new phosphodiesterase type 5 (pde 5) inhibitor for erectile dysfunction. prior studies have also demonstrated a selectivity profile for udenafil that is similar to sildenafil (viagra®) and tadalafil (cialis®). but unlike tadalafil (cialis®), it does not significantly inhibit the pde11 isozyme and not produce significant myalgia. back pain, or leg pain. this prospective, randomized study was designed to evaluate the efficacy of udenafil treatment in treatment of erectile dysfunction after radical resection for sigmoid colon and rectal cancer. in order to conduct this study, enrolled patients will be randomly attributed to udenafil group or placebo group.

Eligibility criteria:
inclusion criteria: * • male patients between 19-70 years old in good general health * patient willing to treat postoperative erectile dysfunction and participate in the study * patient who understands and accepts to sign the informed consent form * patient who received radical resection for sigmoid colon and rectal cancer. : erectile dysfunction was developed following operation, not preoperatively * scores of iief-5 measured at 12 months after surgery is 16 or less exclusion criteria: * • documented problem of preoperative erectile dysfunction * past history of myocardial infarction, cerebrovascular disease * under administration of nitrate * liver dysfunction (sgot or sgpt 100 iu/l or more) * kidney dysfunction (serum creatinine 3mg/dl or more)
eosinophil and anticoagulation in covid-19 patients

Conditions: COVID-19

Summary: despite prophylactic anticoagulant treatments, thrombotic complications may develop in patients with coronavirus disease 2019 (covid-19). this study aimed to evaluate anti-factor xa levels to determine the anticoagulant activity of low molecular weight heparin (lmwh) in covid-19 patients.


Eligibility criteria:
inclusion criteria: * patients older than 18 years, who were diagnosed with covid-19 and were administered lmwh, * agreed to participate in the study were included exclusion criteria: * patients with previous coagulopathy, * continuous indication of anticoagulant therapy (atrial fibrillation (af), valve disease), * glomerular filtration rate (gfr) \<30 ml/min or undergoing dialysis, or with known liver dysfunction were excluded from the study.
effects of flourish on recurrent urinary tract infection

Conditions: Urinary Tract Infections

Summary: an over-the-counter vaginal care system is being tested to see if it may be effective in preventing recurrence of symptomatic urinary tract infection (uti) in women who have had multiple utis within the past year.

women who have a urinary tract infection (uti) may experience a recurrence within weeks or months of treatment. some women may experience 8 or more utis in a single year, leading to multiple rounds of antibiotics, with the individual risks to organs and risk of antibiotic resistance growing with each round. alternative methods for prevention of recurrent uti is therefore desirable. this study will test whether women who use a commercially available, over-the-counter vaginal care system may be able to reduce recurrences of uti over a six-month period. this is a pilot study designed to determine whether a larger randomized controlled trial in the future would be justified.

Eligibility criteria:
inclusion criteria: 1. premenopausal cis women aged 18-52 who are in generally good health 2. history of at least 2 utis in the past six months, or three prior utis in the past year, documented in the medical record. at least one must be culture-proven. exclusion criteria: 1. pregnant or trying to become pregnant 2. lactating 3. immunosuppressed 4. known allergies to aloe vera or to other components of restore®, balance or biophresh® 5. known vaginal infection other than bv or yeast infection at time of screening 6. women who have needed changes to medical intervention or in-office procedures in the last 3 months 7. women using vaginal acidifying agents or spermicides for contraception 8. women who wear a pessary

Keywords: vaginal microbiome microbiome probiotic lactobacillus vulvovaginal symptoms questionnaire vaginal ph
wt1 peptide vaccination in acute myeloid leukemia (aml)

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome

Summary: in this trial, hla-a2+ patients with active aml are vaccinated with a peptide from the leukemia-associated antigen wt1 together with immunological adjuvants keyhole limpet hemocyanin (klh) as t-helper protein and granulocyte macrophage colony stimulating factor (gm-csf) 4 times bi-weekly, then monthly.

in this phase ii trial hla-a2+ patients with active aml without curative treatment option are vaccinated with wt1 126-134 peptide mixed with adjuvant klh as t-helper protein and gm-csf 4 times bi-weekly, then monthly.

Eligibility criteria:
inclusion criteria: * aml or myelodysplastic syndromes (mds) * partial response (pr) or complete response (cr) or smoldering course without option for allogeneic stem cell transplantation * hla-a2+ * wt1-expression in bone marrow
infuence of kinesiotaping on pulmonary function improvement in multiple rib fracture

Conditions: Chest Wall Injury

Summary: elastic tapes, named "kinesiotapes" have a limited, but proven influence on pain reduction, improvement in muscular strength and joint function. it can be hypothetised that by using kinesiotape techniques on damaged chest wall (due to mostly rib fracture) we can improve not only analgesia, but also improve lung function tests and speed recovery.

chest wall injury changes the function of chest wall muscles and other structures, which in turn influences respiratory function and cause significant pain. elastic tapes, named "kinesiotapes" have a limited, but proven influence on pain reduction, improvement in muscular strength and joint function. it can be hypothetised that by using kinesiotape techniques on damaged chest wall (due to mostly rib fracture) we can improve not only analgesia, but also improve lung function tests and speed recovery.

Eligibility criteria:
inclusion criteria: * unilateral chest wall injury with multiple rib fracture (\< 5 ribs) * signed informed consent exclusion criteria: * minors * pregnant women * contraindications of using kinesiotapes * contraindications to perform spirometry (lung function tests) * inability to cooperate * chest drains * pneumothorax
virtual reality for hemophilia

Conditions: Hemophilia A; Hemophilia B

Summary: children with hemophilia are exposed to intravenous (iv) procedures that cause pain/anxiety and distraction methods can be employed to improve the patient experience. three-dimensional virtual reality (vr) environments can reduce distress related to procedures. to be utilized in a clinical setting, however, these devices must address infection control concerns and fit pediatric patients. additionally, for use in hemophilia care, environments should encourage a subject to keep their hands/arms still to facilitate procedures. nursing orchestration of the vr environment via an ipad dashboard has the potential to increase feasibility and acceptance by patients, families and providers of the vr experience without disrupting routine clinical care.

patients with hemophilia a and b (ha/hb) are frequently treated with iv infusions of clotting factor concentrates to treat and prevent bleeding. additionally they typically have at least yearly iv laboratory assessments. pain and anxiety with needle related procedures particularly in children with hemophilia can lead to development of needle phobia, treatment avoidance and poor adherence to treatment regimens. conventional virtual reality (vr) environments have been shown to reduce pain/anxiety in pediatric populations however in a clinical setting children with hemophilia have specific vr design needs that have not been addressed. certain issues related to vr environments are related to the pediatric age range. these include the size and weight of vr headsets, the ease of donning and doffing headsets, and degree of engagement with vr environments. hemophilia specific issues include the need for the vr experience to limit movement of the hands/arms to facilitate iv procedures, customization to prevent boredom/disengagement from repeated use and ability of clinical staff to trigger events via an orchestration dashboard that occur for the patients benefit at key times during iv procedures. lastly, there are issues related to integration into a clinical setting. these include ability to integrate into clinical care without adversely affecting clinic flow, and infection control issues related to headset design.

Eligibility criteria:
inclusion criteria: 1. provide signed and dated informed consent form 2. willing to comply with all study procedures and be available for the duration of the study 3. diagnosed with hemophilia a or b 4. male or female, aged \>6 years to \<19 years 5. subject and caregiver able to understand and speak english 6. being seen for routine comprehensive hemophilia care visits during which an iv procedure is planned as standard of care. exclusion criteria: 1. inability to use the vr equipment (ie visual, cognitive or hearing impairment that would preclude engagement with the vr environment) 2. history of motion sickness as reported by patient or caregiver 3. history of poorly controlled seizures as reported by patient or caregiver
gammaglobulins level is predictive factor of evolution in sarcoidosis

Conditions: Sarcoidosis

Summary: evaluation of the rate of achievement of serum protein electrophoresis (ppe) in diagnosis in a retrospective cohort of patients at rennes university hospital

in 50% of cases, sarcoidosis is associated with polyclonal hypergammaglobulinemia. the other forms have a normal gamma globulin level. the level of gamma globulinemia has not yet been studied as an evolutionary predictive factor. furthermore, there are disseminated granulomatoses sharing common characteristics with sarcoidosis, associated with common variable immunodeficiency deficit (dicv) type primary immunodeficiency syndrome (dip), thus occurring in hypogammaglobulinemic patients.

Eligibility criteria:
inclusion criteria: - patients newly diagnosed with sarcoidosis exclusion criteria: * comorbidity responsible for a change in the level of gamma globulin * other etiology of granulomatosis
effect of dexmedetomidine on postoperative glucose and insulin levels.

Conditions: Bariatric Surgery Candidate; Glucose Intolerance; Insulin Resistance

Summary: this study investigated the effect of dexmedetomidine in obese patients undergoing bariatric surgery.

a prospective, double-blind, randomized controlled trial was performed. consenting obese adult patients with impaired glucose tolerance, undergoing bariatric surgery, were randomized, by a computer, to receive placebo (0.9% sodium-chloride) or dexmedetomidine 1 ug/kg bolus in 10 minutes followed by an infusion of 0.5 ug/kg/h until the end of surgery. baseline hgba1c, glucose, and insulin plasmatic levels were measured. subsequently, glucose and insulin levels were taken every 2 hours during the first 12 hours from the onset of the drug infusion. intraoperative fentanyl and postoperative morphine consumption, pain score, the occurrence of emesis, and postoperative sedation levels were recorded as secondary outcomes.

Eligibility criteria:
inclusion criteria: * obese patient (bmi\>30) * american society of anesthesiologists grades ii or iii * diagnosis of impaired glucose tolerance * undergoing sleeve gastrectomy exclusion criteria: * baseline glucose \> 200mg/dl * diagnosis of diabetes * under corticosteroids treatment * oral hypoglycemic medication within 7 days previous surgery * use of insulin within 24h previous surgery * allergy to any drug used in the study

Keywords: impaired glucose tolerance obese patients dexmedetomidine
clinical trials evaluating the effect of metformin treatment on function endometrium in women diagnosed with idiopathic infertility

Conditions: Infertility, Female

Summary: randomized, controlled, double-blind, three-arm clinical trial in which 75 women will be randomized to treatment with metformin, 75 women to treatment with placebo and 50 women to the observation group. the medical intervention will last 24 weeks (6 months). women with confirmed idiopathic infertility, in whom infertility factors have been excluded during full diagnostics, will be included in the study


Eligibility criteria:
inclusion criteria: 1. age 18-45 2. no pregnancy for a minimum of 12 months prior to screening. 3. diagnosed with idiopathic infertility. 4. no use of hormone therapy 30 days before screening. 5. no use of any methods of contraception 30 days before screening and during the examination. 6. bmi between 18.5 - 30 kg/m2. exclusion criteria: 1. positive pregnancy test result. 2. patients diagnosed with another factor of infertility. 3. patients with type i or ii diabetes. 4. patients taking metformin or other hypoglycaemic drugs in the last 4 weeks before screening. 5. patients with hepatic impairment and abnormal liver function tests (alanine aminotransferase and/or aspartate aminotransferase (above 3x uln). 6. patients with an egfr less than 45 ml/min/1.73m2. 7. accompanying chronic diseases with poor prognosis. 8. patients with a history of lactic acidosis or other metabolic acidosis. 9. patients with a history of congestive heart failure iii/iv nyha degree. 10. patients with acute myocardial ischemia. 11. patients with sepsis or severe infection. 12. diseases which, in the opinion of the investigator, constitute an exclusion criterion and prevent the patient from participating in the study. 13. patients with predictable problems with cooperation with the research team.
oxygen consumption in adolescent idiopathic scoliosis

Conditions: Adolescent Idiopathic Scoliosis

Summary: adolescent idiopathic scoliosis (ais) is a rotational deformity of the spine that could be seen 2-3% of population. conservative treatment of ais with 20-45 degree lateral flexion angle (cobb) includes brace and therapeutic exercises. some gait abnormalities were defined like decreased torsional movements of spine, increased muscular work and energy expenditure in ais. additionally wearing a brace limits pelvic motions and affects pendulum-like mechanism of gait. our aim was to investigate gait energy consumption, pulmonary functions, balance and lower extremity loading symmetry in ais subjects who are getting conservative treatment.


Eligibility criteria:
inclusion criteria: * cobb angle between 20-45 degree, * prescribed a rigid spinal brace by doctor exclusion criteria: * having leg length discrepancy more than 1 centimeter * having a lung disease * having another orthopedic or neurologic disorder